Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)Retained EarningsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming (PHAR) Receivables - Other (2019 - 2024)

Historic Receivables - Other for Pharming (PHAR) over the last 6 years, with Q4 2024 value amounting to $1.6 million.

  • Pharming's Receivables - Other fell 2559.44% to $1.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.6 million, marking a year-over-year decrease of 2559.44%. This contributed to the annual value of $1.6 million for FY2024, which is 2559.44% down from last year.
  • Latest data reveals that Pharming reported Receivables - Other of $1.6 million as of Q4 2024, which was down 2559.44% from $2.1 million recorded in Q4 2023.
  • In the past 5 years, Pharming's Receivables - Other registered a high of $2.4 million during Q4 2021, and its lowest value of $1.1 million during Q4 2022.
  • For the 5-year period, Pharming's Receivables - Other averaged around $1.9 million, with its median value being $2.1 million (2023).
  • As far as peak fluctuations go, Pharming's Receivables - Other surged by 16189.38% in 2020, and later tumbled by 5272.96% in 2022.
  • Quarter analysis of 5 years shows Pharming's Receivables - Other stood at $2.2 million in 2020, then grew by 5.59% to $2.4 million in 2021, then tumbled by 52.73% to $1.1 million in 2022, then skyrocketed by 92.03% to $2.1 million in 2023, then decreased by 25.59% to $1.6 million in 2024.
  • Its Receivables - Other stands at $1.6 million for Q4 2024, versus $2.1 million for Q4 2023 and $1.1 million for Q4 2022.